title: Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United States.
abstract: This study assessed the cost-effectiveness of Octaplas™ versus fresh frozen plasma (FFP) in patients receiving plasma transfusions in the United States (US). Acute and long-term complications of plasma transfusions were modelled in a decision tree followed by a Markov model, using a healthcare payer perspective. Over a lifetime time horizon, patients receiving Octaplas™ accumulate slightly more life years (0.00613 [95% uncertainty interval (95%UI): 0.00166-0.01561]) and quality-adjusted life years (QALY) (0.023 [95%UI: 0.012-0.044]) at lower cost compared with those treated with FFP. Octaplas™ demonstrated to be the dominant treatment option over FFP (95%UI: Dominant-US$ 15,764/QALY).
authors.affiliation: Mapi, De Molen 84, 3995 AX Houten, The Netherlands. Electronic address: ehuisman@mapigroup.com.
authors.forename: Eline L
authors.initials: EL
authors.lastname: Huisman
authors.affiliation: Mapi, 73 Collier Street, London N1 9BE, UK.
authors.forename: Shamika U
authors.initials: SU
authors.lastname: de Silva
authors.affiliation: Mapi, De Molen 84, 3995 AX Houten, The Netherlands.
authors.forename: Maria A
authors.initials: MA
authors.lastname: de Peuter
mesh_terms: D000328:Adult; D016913:Blood Component Transfusion / Q000191:economics*; D003365:Costs and Cost Analysis; D003902:Detergents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018803:Models, Economic; D010949:Plasma; D012997:Solvents; D014481:United States
chemical_list: D003902:Detergents; D012997:Solvents
keywords: Cost-effectiveness analysis; Fresh-frozen plasma; Octaplas™; Transfusion; United States